Perspective Therapeutics, Inc. Common Stock CATX 深 沪
等待开盘 07-22 09:30:00 美东时间
4.31
+0.110
+2.62%
华盛通- 最 高4.64
- 今 开4.20
- 成交量 121.63万股
- 最 低 4.20
- 昨 收 4.20
- 总市值 3.20亿
- 52周最高 16.55
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 1.60
- 委 比 -55.56%
- 总股本 7422.83万
- 历史最高 37.90
- 量 比 1.04
- 振 幅 10.48%
- 历史最低 1.60
- 每 手 1
- 风险率 4.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
Perspective Therapeutics, Inc. (NYSE American: CATX), a radiopharmaceutical company, announced it will report Q2 2025 financial results and provide a business update on August 13, 2025. The press release will be available on their website. The company specializes in advanced cancer treatments using alpha-emitting isotope 212Pb and is developing theranostic approaches combining imaging and therapy to improve treatment efficacy. Their programs for ...
07-15 11:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to c...
06-25 00:52
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
Perspective Therapeutics Advances Phase 1/2a Clinical Trial
Perspective Therapeutics ( ($CATX) ) has provided an announcement. On June 21, ...
06-24 02:23
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
06-23 21:40
Reported Saturday, Perspective Therapeutics Opens Cohort 3 In Phase 1/2a Trial of [212Pb]VMT-α-NET For SSTR2-Positive Neuroendocrine Tumors With 20% Higher Fixed Dose
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the
06-23 16:18
美股牛股 | “英伟达亲儿子”CoreWeave涨超25%，公司签下70亿美元大单；能源股VG绩后大涨21%
“英伟达亲儿子”CoreWeave涨超25%，公司签下70亿美元大单；能源股VG绩后大涨21%，Q1营收大增超100%>>
06-04 19:21
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
Perspective Therapeutics Updates on Radiopharmaceutical Advancements
Perspective Therapeutics ( ($CATX) ) has provided an announcement. On June 3, 2...
06-03 20:28
